{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:23:33Z","timestamp":1776205413906,"version":"3.50.1"},"reference-count":168,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1085359"],"award-info":[{"award-number":["1085359"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Centre for HIV and Hepatitis Research","award":["JIN2018"],"award-info":[{"award-number":["JIN2018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The human immunodeficiency virus type 1 (HIV) establishes a chronic infection that can be well controlled, but not cured, by combined antiretroviral therapy (cART). Interventions have been explored to accomplish a functional cure, meaning that a patient remains infected but HIV is undetectable in the blood, with the aim of allowing patients to live without cART. Tat, the viral transactivator of transcription protein, plays a critical role in controlling HIV transcription, latency, and viral rebound following the interruption of cART treatment. Therefore, a logical approach for controlling HIV would be to block Tat. Tackling Tat with inhibitors has been a difficult task, but some recent discoveries hold promise. Two anti-HIV proteins, Nullbasic (a mutant of Tat) and HT1 (a fusion of HEXIM1 and Tat functional domains) inhibit viral transcription by interfering with the interaction of Tat and cellular factors. Two small molecules, didehydro-cortistatin A (dCA) and triptolide, inhibit Tat by different mechanisms: dCA through direct binding and triptolide through enhanced proteasomal degradation. Finally, two Tat-based vaccines under development elicit Tat-neutralizing antibodies. These vaccines have increased the levels of CD4+ cells and reduced viral loads in HIV-infected people, suggesting that the new vaccines are therapeutic. This review summarizes recent developments of anti-Tat agents and how they could contribute to a functional cure for HIV.<\/jats:p>","DOI":"10.3390\/v12040415","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T03:40:19Z","timestamp":1586403619000},"page":"415","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure"],"prefix":"10.3390","volume":"12","author":[{"given":"Hongping","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Hsuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-0150","authenticated-orcid":false,"given":"David","family":"Harrich","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/157016208785861195","article-title":"Cellular reservoirs of HIV-1 and their role in viral persistence","volume":"6","author":"Alexaki","year":"2008","journal-title":"Curr. HIV Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12977-017-0344-7","article-title":"A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy","volume":"14","author":"Edagwa","year":"2017","journal-title":"Retrovirology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/COH.0000000000000293","article-title":"Tissue reservoirs of HIV","volume":"11","author":"Wong","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/infdis\/jiv218","article-title":"Precise quantitation of the latent HIV-1 reservoir: Implications for eradication strategies","volume":"212","author":"Crooks","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/infdis\/jiv219","article-title":"The remarkable stability of the latent reservoir for HIV-1 in resting memory CD4+ T cells","volume":"212","author":"Siliciano","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1038\/s41467-019-12732-2","article-title":"Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa","volume":"10","author":"Rosero","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.chom.2016.07.015","article-title":"Single-cell characterization of viral translation-competent reservoirs in HIV-infected individuals","volume":"20","author":"Baxter","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41564-018-0335-z","article-title":"HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy","volume":"4","author":"Ganor","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11481-018-9809-2","article-title":"Macrophages but not astrocytes harbor HIV DNA in the brains of HIV-1-infected aviremic individuals on suppressive antiretroviral therapy","volume":"14","author":"Ko","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature10347","article-title":"Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy","volume":"477","author":"Sigal","year":"2011","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","article-title":"Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection","volume":"24","author":"Colby","year":"2018","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1742-4690-10-67","article-title":"HIV-1 transcription and latency: An update","volume":"10","author":"Bouchat","year":"2013","journal-title":"Retrovirology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/COH.0b013e3283412384","article-title":"Epigenetic regulation of HIV latency","volume":"6","author":"Hakre","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1126\/science.1191047","article-title":"HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals","volume":"329","author":"Trono","year":"2010","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI80565","article-title":"Molecular mechanisms of HIV latency","volume":"126","author":"Cary","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ebiom.2019.06.020","article-title":"Deep latency: A new insight into a functional HIV cure","volume":"45","author":"Elsheikh","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1128\/JVI.01594-12","article-title":"An AP-1 binding site in the enhancer\/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection","volume":"87","author":"Duverger","year":"2013","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1002\/j.1460-2075.1993.tb05994.x","article-title":"Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation activation [published erratum appears in EMBO J. 1993, 12, 4900]","volume":"12","author":"Verdin","year":"1993","journal-title":"EMBO J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/j.1460-2075.1996.tb00449.x","article-title":"Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation","volume":"15","author":"Emiliani","year":"1996","journal-title":"EMBO J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cell.2015.02.009","article-title":"A hardwired HIV latency program","volume":"160","author":"Razooky","year":"2015","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12453","DOI":"10.1073\/pnas.1811195115","article-title":"Probabilistic control of HIV latency and transactivation by the Tat gene circuit","volume":"115","author":"Cao","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Chavez, L., Calvanese, V., and Verdin, E. (2015). HIV latency is established directly and early in both resting and activated primary CD4 T cells. PLOS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004955"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.immuni.2017.09.014","article-title":"Transcriptional reprogramming during effector-to-memory transition renders CD4+ T cells permissive for latent HIV-1 infection","volume":"47","author":"Shan","year":"2017","journal-title":"Immunity"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Dobrowolski, C., Valadkhan, S., Graham, A.C., Shukla, M., Ciuffi, A., Telenti, A., and Karn, J. (2019). Entry of polarized effector cells into quiescence forces HIV latency. mBio, 10.","DOI":"10.1128\/mBio.00337-19"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.celrep.2018.09.020","article-title":"Single-cell analysis of quiescent HIV infection reveals host transcriptional profiles that regulate proviral latency","volume":"25","author":"Bradley","year":"2018","journal-title":"Cell Rep."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Norton, N.J., Mok, H.P., Sharif, F., Hirst, J.C., and Lever, A.M.L. (2019). HIV silencing and inducibility are heterogeneous and are affected by factors intrinsic to the virus. mBio, 10.","DOI":"10.1128\/mBio.00188-19"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27569","DOI":"10.18632\/oncotarget.15174","article-title":"Tat is a multifunctional viral protein that modulates cellular gene expression and functions","volume":"8","author":"Clark","year":"2017","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2217\/fvl.13.65","article-title":"Revisiting transdominant-negative proteins in HIV gene therapy","volume":"8","author":"Sivakumaran","year":"2013","journal-title":"Future Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2031","DOI":"10.1002\/rmv.2031","article-title":"Tat basic domain: A \u201cSwiss army knife\u201d of HIV-1 Tat?","volume":"29","author":"Kurnaeva","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1073\/pnas.88.9.4045","article-title":"The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation","volume":"88","author":"Feinberg","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/330489a0","article-title":"Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product","volume":"330","author":"Kao","year":"1987","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0092-8674(89)90290-0","article-title":"HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation","volume":"59","author":"Laspia","year":"1989","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1002\/j.1460-2075.1991.tb04997.x","article-title":"HIV-1 Tat protein promotes formation of more-processive elongation complexes","volume":"10","author":"Marciniak","year":"1991","journal-title":"EMBO J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1073\/pnas.91.9.3862","article-title":"Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts","volume":"91","author":"Adams","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/326711a0","article-title":"An inducible transcription factor activates expression of human immunodeficiency virus in T cells","volume":"326","author":"Nabel","year":"1987","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2005.06.006","article-title":"Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity","volume":"122","author":"Weinberger","year":"2005","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/21541264.2017.1281864","article-title":"P-tefb: Finding its ways to release promoter-proximally paused RNA polymerase II","volume":"9","author":"Li","year":"2018","journal-title":"Transcription"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.2174\/1381612823666170704130635","article-title":"The HIV-1 Tat protein: Mechanism of action and target for HIV-1 cure strategies","volume":"23","author":"Rice","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev-med-092112-152941","article-title":"Understanding HIV latency: The road to an HIV cure","volume":"66","author":"Dahabieh","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Planelles, V. (2015). An ounce of Tat prevention is worth a pound of functional cure. mBio, 6.","DOI":"10.1128\/mBio.01269-15"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ebiom.2016.04.039","article-title":"Ledgin-mediated inhibition of integrase-ledgf\/p75 interaction reduces reactivation of residual latent HIV","volume":"8","author":"Vranckx","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.it.2016.12.003","article-title":"HIV latency: Should we shock or lock?","volume":"38","author":"Darcis","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_45","first-page":"121","article-title":"Targeting HIV transcription: The quest for a functional cure","volume":"389","author":"Mousseau","year":"2015","journal-title":"Curr Top. Microbiol. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e00465","DOI":"10.1128\/mBio.00465-15","article-title":"The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency","volume":"6","author":"Mousseau","year":"2015","journal-title":"MBio"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.3389\/fmicb.2017.02007","article-title":"Curaxin CBL0100 blocks HIV-1 replication and reactivation through inhibition of viral transcriptional elongation","volume":"8","author":"Jean","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"28896","DOI":"10.1038\/srep28896","article-title":"Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"E1528","DOI":"10.1073\/pnas.1320178111","article-title":"Heat shock protein 90 controls HIV-1 reactivation from latency","volume":"111","author":"Anderson","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.chom.2016.11.001","article-title":"The mTOR complex controls HIV latency","volume":"20","author":"Besnard","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"aaf6517","DOI":"10.1126\/science.aaf6517","article-title":"Latency reversal and viral clearance to cure HIV-1","volume":"353","author":"Margolis","year":"2016","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","article-title":"Getting the \u201ckill\u201d into \u201cshock and kill\u201d: Strategies to eliminate latent HIV","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jtbi.2019.04.018","article-title":"Modeling the effect of Tat inhibitors on HIV latency","volume":"473","author":"Aguilera","year":"2019","journal-title":"J. Theor. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4155\/fmc.16.3","article-title":"Recent advances in the identification of Tat-mediated transactivation inhibitors: Progressing toward a functional cure of HIV","volume":"8","author":"Tabarrini","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1073\/pnas.87.13.5079","article-title":"A transdominant Tat mutant that inhibits Tat-induced gene expression from the human immunodeficiency virus long terminal repeat","volume":"87","author":"Pearson","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","first-page":"759","article-title":"Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression","volume":"3","author":"Modesti","year":"1991","journal-title":"New Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1099\/0022-1317-73-1-77","article-title":"Cells surviving infection by human immunodeficiency virus type 1: Vif or Vpu mutants produce non-infectious or markedly less cytopathic viruses","volume":"73","author":"Kishi","year":"1992","journal-title":"J. Gen. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9870","DOI":"10.1073\/pnas.89.20.9870","article-title":"Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator","volume":"89","author":"Bevec","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.176.4.1197","article-title":"Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication","volume":"176","author":"Malim","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1128\/jvi.70.7.4871-4876.1996","article-title":"Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins","volume":"70","author":"Ulich","year":"1996","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/emboj\/16.6.1224","article-title":"Tat is required for efficient HIV-1 reverse transcription","volume":"16","author":"Harrich","year":"1997","journal-title":"EMBO J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/157016207781662443","article-title":"The HIV-1 Tat protein stimulates reverse transcription in vitro","volume":"5","author":"Apolloni","year":"2007","journal-title":"Curr. HIV Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/nar\/gkt934","article-title":"Dynamic interactions of the HIV-1 Tat with nucleic acids are critical for Tat activity in reverse transcription","volume":"42","author":"Boudier","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Meredith, L.W., Sivakumaran, H., Major, L., Suhrbier, A., and Harrich, D. (2009). Potent inhibition of HIV-1 replication by a Tat mutant. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007769"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1128\/JVI.03440-14","article-title":"A mutant Tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex","volume":"89","author":"Lin","year":"2015","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12977-014-0121-9","article-title":"A HIV-1 Tat mutant protein disrupts HIV-1 Rev function by targeting the DEAD-box RNA helicase DDX1","volume":"11","author":"Lin","year":"2014","journal-title":"Retrovirology"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Lin, M.H., Sivakumaran, H., Apolloni, A., Wei, T., Jans, D.A., and Harrich, D. (2012). Nullbasic, a potent anti-HIV Tat mutant, induces CRM1-dependent disruption of HIV Rev trafficking. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0051466"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1089\/hum.2012.176","article-title":"A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells","volume":"24","author":"Apolloni","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Jin, H., Li, D., Sivakumaran, H., Lor, M., Rustanti, L., Cloonan, N., Wani, S., and Harrich, D. (2016). Shutdown of HIV-1 transcription in T cells by Nullbasic, a mutant Tat protein. MBio, 7.","DOI":"10.1128\/mBio.00518-16"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Jin, H., Sun, Y., Li, D., Lin, M.-H., Lor, M., Rustanti, L., and Harrich, D. (2019). Strong in vivo inhibition of HIV-1 replication by Nullbasic, a Tat mutant. mBio, 10.","DOI":"10.1128\/mBio.01769-19"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1742-4690-2-42","article-title":"Inhibition of Tat activity by the HEXIM1 protein","volume":"2","author":"Fraldi","year":"2005","journal-title":"Retrovirology"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Leoz, M., Kukanja, P., Luo, Z., Huang, F., Cary, D.C., Peterlin, B.M., and Fujinaga, K. (2018). HEXIM1-Tat chimera inhibits HIV-1 replication. PLOS Pathogens, 14.","DOI":"10.1371\/journal.ppat.1007402"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chom.2012.05.016","article-title":"An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription","volume":"12","author":"Mousseau","year":"2012","journal-title":"Cell Host Microbe"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Mediouni, S., Chinthalapudi, K., Ekka, M.K., Usui, I., Jablonski, J.A., Clementz, M.A., Mousseau, G., Nowak, J., Macherla, V.R., and Beverage, J.N. (2019). Didehydro-cortistatin A inhibits HIV-1 by specifically binding to the unstructured basic region of Tat. MBio, 10.","DOI":"10.1128\/mBio.02662-18"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13072-019-0267-8","article-title":"Tat inhibition by didehydro-cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat","volume":"12","author":"Li","year":"2019","journal-title":"Epigenetics Chromatin"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8280","DOI":"10.1096\/fj.201801165R","article-title":"The Tat inhibitor didehydro-cortistatin A suppresses SIV replication and reactivation","volume":"33","author":"Mediouni","year":"2019","journal-title":"FASEB J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12977-014-0088-6","article-title":"Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein","volume":"11","author":"Wan","year":"2014","journal-title":"Retrovirology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.vaccine.2009.10.038","article-title":"The preventive phase I trial with the HIV-1 Tat-based vaccine","volume":"28","author":"Ensoli","year":"2009","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12977-016-0261-1","article-title":"HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: A randomized phase II clinical trial","volume":"13","author":"Ensoli","year":"2016","journal-title":"Retrovirology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/9488","article-title":"Control of SHIV-89.6p-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine","volume":"5","author":"Cafaro","year":"1999","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1016\/j.vaccine.2004.03.009","article-title":"Long-term protection against SHIV89.6p replication in HIV-1 Tat vaccinated cynomolgus monkeys","volume":"22","author":"Maggiorella","year":"2004","journal-title":"Vaccine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12977-015-0151-y","article-title":"HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial","volume":"12","author":"Ensoli","year":"2015","journal-title":"Retrovirology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fimmu.2019.00233","article-title":"Continued decay of HIV proviral DNA upon vaccination with HIV-1 Tat of subjects on long-term ART: An 8-year follow-up study","volume":"10","author":"Sgadari","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Ensoli, B., Bellino, S., Tripiciano, A., Longo, O., Francavilla, V., Marcotullio, S., Cafaro, A., Picconi, O., Paniccia, G., and Scoglio, A. (2010). Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013540"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"35915","DOI":"10.1074\/jbc.M204393200","article-title":"Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants","volume":"277","author":"Opi","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12977-016-0251-3","article-title":"Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies\/mL the HIV RNA rebound median and no HIV DNA rebound following cart interruption in a phase I\/II randomized controlled clinical trial","volume":"13","author":"Loret","year":"2016","journal-title":"Retrovirology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-4690-3-8","article-title":"Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine","volume":"3","author":"Watkins","year":"2006","journal-title":"Retrovirology"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Spina, C.A., Anderson, J., Archin, N.M., Bosque, A., Chan, J., Famiglietti, M., Greene, W.C., Kashuba, A., Lewin, S.R., and Margolis, D.M. (2013). An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003834"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1189\/jlb.0312165","article-title":"BET bromodomain inhibition as a novel strategy for reactivation of HIV-1","volume":"92","author":"Banerjee","year":"2012","journal-title":"J. Leukoc Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00002030-200405210-00003","article-title":"Coaxing HIV-1 from resting CD4 T cells: Histone deacetylase inhibition allows latent viral expression","volume":"18","author":"Ylisastigui","year":"2004","journal-title":"AIDS"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/aid.2008.0191","article-title":"Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid","volume":"25","author":"Archin","year":"2009","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1074\/jbc.M807898200","article-title":"Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells","volume":"284","author":"Contreras","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12985-017-0705-9","article-title":"A mutant Tat protein inhibits infection of human cells by strains from diverse HIV-1 subtypes","volume":"14","author":"Rustanti","year":"2017","journal-title":"Virol. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1093\/nar\/gkw585","article-title":"Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb","volume":"44","author":"AJ","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1128\/MCB.24.12.5094-5105.2004","article-title":"A human immunodeficiency virus type 1 Tat-like arginine-rich RNA-binding domain is essential for HEXIM1 to inhibit RNA polymerase II transcription through 7SK snRNA-mediated inactivation of P-TEFb","volume":"24","author":"Yik","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1038\/sj.emboj.7600275","article-title":"Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9\/cyclin T) inhibitor","volume":"23","author":"Michels","year":"2004","journal-title":"EMBO J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S1097-2765(03)00388-5","article-title":"Inhibition of P-TEFb (CDK9\/cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA","volume":"12","author":"Yik","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nature09131","article-title":"Crystal structure of HIV-1 Tat complexed with human P-TEFb","volume":"465","author":"Tahirov","year":"2010","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1021\/ja202103e","article-title":"Scalable synthesis of cortistatin A and related structures","volume":"133","author":"Shi","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature14904","article-title":"Mediator kinase inhibition further activates super-enhancer-associated genes in AML","volume":"526","author":"Pelish","year":"2015","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1002\/anie.200904778","article-title":"Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11","volume":"48","author":"Cee","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/aid.2019.0039","article-title":"HIV transcription is independent of mediator kinases","volume":"35","author":"Cary","year":"2019","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1570162X13666150121111548","article-title":"Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice","volume":"13","author":"Mediouni","year":"2015","journal-title":"Curr. HIV Res."},{"key":"ref_105","first-page":"229","article-title":"Chromatin regulation and the histone code in HIV latency","volume":"90","author":"Turner","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.virol.2010.06.009","article-title":"Transcription through the HIV-1 nucleosomes: Effects of the PBAF complex in Tat activated transcription","volume":"405","author":"Easley","year":"2010","journal-title":"Virology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2017.09.080","article-title":"In vivo suppression of HIV rebound by didehydro-cortistatin A, a \u201cblock-and-lock\u201d strategy for HIV-1 treatment","volume":"21","author":"Kessing","year":"2017","journal-title":"Cell Rep."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Rice, A.P. (2019). Unexpected mutations in HIV-1 that confer resistance to the Tat inhibitor didehydro-cortistatin A. MBio, 10.","DOI":"10.1128\/mBio.01547-19"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Mousseau, G., Aneja, R., Clementz, M.A., Mediouni, S., Lima, N.S., Haregot, A., Kessing, C.F., Jablonski, J.A., Thenin-Houssier, S., and Nagarsheth, N. (2019). Resistance to the Tat inhibitor didehydro-cortistatin A is mediated by heightened basal HIV-1 transcription. MBio, 10.","DOI":"10.1128\/mBio.01750-18"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00296-011-1841-y","article-title":"A chinese herb Tripterygium wilfordii hook F in the treatment of rheumatoid arthritis: Mechanism, efficacy, and safety","volume":"31","author":"Bao","year":"2011","journal-title":"Rheumatol. Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/art.10411","article-title":"Benefit of an extract of Tripterygium wilfordii hook F in patients with rheumatoid arthritis: A double-blind, placebo-controlled study","volume":"46","author":"Tao","year":"2002","journal-title":"Arthritis Rheum"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fphar.2018.00104","article-title":"A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii hook F","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Kim, S.T., Kim, S.Y., Lee, J., Kim, K., Park, S.H., Park, Y.S., Lim, H.Y., Kang, W.K., and Park, J.O. (2018). Triptolide as a novel agent in pancreatic cancer: The validation using patient derived pancreatic tumor cell line. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4995-0"},{"key":"ref_114","first-page":"149","article-title":"Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: A mini review","volume":"6","author":"Ziaei","year":"2016","journal-title":"Avicenna J. Phytomed."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"13443","DOI":"10.1074\/jbc.274.19.13443","article-title":"Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box\/nuclear factor of activated T-cells and NF-\u03baB transcriptional activation","volume":"274","author":"Qiu","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1535-7163.MCT-09-0549","article-title":"Triptolide is an inhibitor of RNA polymerase I and II\u2013dependent transcription leading predominantly to down-regulation of short-lived mRNA","volume":"8","author":"DeVries","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Wang, Y., Lu, J.-j., He, L., and Yu, Q. (2011). Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023993"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41580-018-0010-5","article-title":"Born to run: Control of transcription elongation by RNA polymerase II","volume":"19","author":"Chen","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13046-019-1232-x","article-title":"Inhibition of RNA polymerase III transcription by triptolide attenuates colorectal tumorigenesis","volume":"38","author":"Liang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nchembio.522","article-title":"XPB, a subunit of TFIIH, is a target of the natural product triptolide","volume":"7","author":"Titov","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1101\/gad.246173.114","article-title":"Stably paused genes revealed through inhibition of transcription initiation by the TFIIH inhibitor triptolide","volume":"29","author":"Chen","year":"2015","journal-title":"Genes Dev."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"Derdeyn","year":"2000","journal-title":"J. Virol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt","year":"1998","journal-title":"J. Virol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1743-422X-10-207","article-title":"Overexpression of PRMT6 does not suppress HIV-1 Tat transactivation in cells naturally lacking PRMT6","volume":"10","author":"Sivakumaran","year":"2013","journal-title":"Virol. J."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Fan, D., Guo, Q., Shen, J., Zheng, K., Lu, C., Zhang, G., Lu, A., and He, X. (2018). The effect of triptolide in rheumatoid arthritis: From basic research towards clinical translation. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020376"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nm0996-960","article-title":"HIV-1 Tat protein as a potential AIDS vaccine","volume":"2","author":"Goldstein","year":"1996","journal-title":"Nat. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.mib.2009.06.016","article-title":"Stochastic gene expression as a molecular switch for viral latency","volume":"12","author":"Singh","year":"2009","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/345084a0","article-title":"Tat protein of HIV-1 stimulates growth of cells derived from Kaposi\u2019s sarcoma lesions of AIDS patients","volume":"345","author":"Ensoli","year":"1990","journal-title":"Nature"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/375497a0","article-title":"Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120","volume":"375","author":"Westendorp","year":"1995","journal-title":"Nature"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"11466","DOI":"10.1073\/pnas.97.21.11466","article-title":"Selective CXCR4 antagonism by Tat: Implications for in vivo expansion of coreceptor use by HIV-1","volume":"97","author":"Xiao","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1042\/CBI20090376","article-title":"HIV-1 Tat is unconventionally secreted through the plasma membrane","volume":"34","author":"Rayne","year":"2010","journal-title":"Cell Biol. Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/tra.12578","article-title":"Defining the molecular mechanisms of HIV-1 Tat secretion: Ptdins(4,5)p2 at the epicenter","volume":"19","author":"Mele","year":"2018","journal-title":"Traffic"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1073\/pnas.94.15.8116","article-title":"Tat protein induces self-perpetuating permissivity for productive HIV-1 infection","volume":"94","author":"Li","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1126\/science.7716549","article-title":"Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein","volume":"268","author":"Li","year":"1995","journal-title":"Science"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.8493575","article-title":"Repression of MHC class I gene promoter activity by two-exon tat of HIV","volume":"260","author":"Howcroft","year":"1993","journal-title":"Science"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.expneurol.2004.11.019","article-title":"Permeability of the blood-brain barrier to HIV-1 Tat","volume":"193","author":"Banks","year":"2005","journal-title":"Exp. Neurol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.brainres.2005.03.031","article-title":"HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells","volume":"1045","author":"Price","year":"2005","journal-title":"Brain Res."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Rojas-Celis, V., Valiente-Echeverria, F., Soto-Rifo, R., and Toro-Ascuy, D. (2019). New challenges of HIV-1 infection: How HIV-1 attacks and resides in the central nervous system. Cells, 8.","DOI":"10.3390\/cells8101245"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1128\/jvi.64.2.962-965.1990","article-title":"Characterization of murine monoclonal antibodies to the Tat protein from human immunodeficiency virus type 1","volume":"64","author":"Brake","year":"1990","journal-title":"J. Virol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jmv.1890260306","article-title":"Natural antibodies to HIV-Tat epitopes and expression of HIV-1 genes in vivo","volume":"26","author":"Krone","year":"1988","journal-title":"J. Med. Virol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/jmv.1890300303","article-title":"Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1","volume":"30","author":"Reiss","year":"1990","journal-title":"J. Med. Virol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00042560-199512000-00003","article-title":"Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo","volume":"10","author":"Re","year":"1995","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"ref_144","first-page":"282","article-title":"Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine","volume":"1","author":"Zagury","year":"1998","journal-title":"J. Hum. Virol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1386-6532(00)00189-X","article-title":"Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients","volume":"21","author":"Re","year":"2001","journal-title":"J. Clin. Virol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.288.5463.55d","article-title":"HIV-1 nomenclature proposal","volume":"288","author":"Robertson","year":"2000","journal-title":"Science"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/313277a0","article-title":"Complete nucleotide sequence of the AIDS virus, HTLV-III","volume":"313","author":"Ratner","year":"1985","journal-title":"Nature"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/00002030-198911000-00004","article-title":"A highly defective HIV-1 strain isolated from a healthy Gabonese individual presenting an atypical western blot","volume":"3","author":"Huet","year":"1989","journal-title":"AIDS"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/j.1460-2075.1988.tb03181.x","article-title":"Functional domains required for Tat-induced transcriptional activation of the HIV-1 long terminal repeat","volume":"7","author":"Garcia","year":"1988","journal-title":"EMBO J."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Foley, B., Leitner, T., Apetrei, C., Hahn, B., Mizrachi, I., Mullins, J., Rambaut, A., Wolinsky, S., and Korber, B. (2018). HIV Sequence Compendium 2018, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory.","DOI":"10.2172\/1458915"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1073\/pnas.97.7.3515","article-title":"Vaccination with Tat toxoid attenuates disease in simian\/HIV-challenged macaques","volume":"97","author":"Pauza","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1016\/S0264-410X(02)00219-0","article-title":"Comparison of the efficacy of early versus late viral proteins in vaccination against SIV","volume":"20","author":"Stittelaar","year":"2002","journal-title":"Vaccine"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"12321","DOI":"10.1128\/JVI.79.19.12321-12331.2005","article-title":"Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6p challenge in mamu-a*01-negative rhesus monkeys","volume":"79","author":"Liang","year":"2005","journal-title":"J. Virol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Cafaro, A., Tripiciano, A., Picconi, O., Sgadari, C., Moretti, S., Butt\u00f2, S., Monini, P., and Ensoli, B. (2019). Anti-Tat immunity in HIV-1 infection: Effects of naturally occurring and vaccine-induced antibodies against Tat on the course of the disease. Vaccines, 7.","DOI":"10.3390\/vaccines7030099"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1742-4690-11-49","article-title":"The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study","volume":"11","author":"Bellino","year":"2014","journal-title":"Retrovirology"},{"key":"ref_156","first-page":"137","article-title":"Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi\u2019s sarcoma","volume":"3","author":"Demirhan","year":"2000","journal-title":"J. Hum. Virol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Chen, Q., Li, L., Liao, W., Zhang, H., Wang, J., Sheng, B., Zhang, H., Huang, X., Ding, Y., and Zhang, T. (2013). Characterization of Tat antibody responses in Chinese individuals infected with HIV-1. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060825"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/378412","article-title":"Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected italians, ugandans, and south africans","volume":"188","author":"Butto","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1086\/428909","article-title":"The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: Findings in a cohort of HIV-1 seroconverters","volume":"191","author":"Rezza","year":"2005","journal-title":"J. Infect. Dis"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1128\/jvi.62.12.4523-4532.1988","article-title":"Functional comparison of transactivation by simian immunodeficiency virus from rhesus macaques and human immunodeficiency virus type 1","volume":"62","author":"Viglianti","year":"1988","journal-title":"J. Virol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Kamori, D., and Ueno, T. (2017). HIV-1 Tat and viral latency: What we can learn from naturally occurring sequence variations. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.00080"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1073\/pnas.90.16.7719","article-title":"Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein","volume":"90","author":"Rodman","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"8347","DOI":"10.1074\/jbc.M510748200","article-title":"HIV-1 Tat is a natively unfolded protein: The solution conformation and dynamics of reduced HIV-1 Tat1-72 by NMR spectroscopy","volume":"281","author":"Shojania","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2018.1917","article-title":"HIV pre-exposure prophylaxis: A review","volume":"319","author":"Riddell","year":"2018","journal-title":"JAMA"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/COH.0000000000000119","article-title":"Changes in HIV reservoirs during long-term antiretroviral therapy","volume":"10","author":"Hong","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"11336","DOI":"10.1128\/JVI.75.23.11336-11343.2001","article-title":"Induction of TAK (cyclin T1\/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines","volume":"75","author":"Ghose","year":"2001","journal-title":"J. Virol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1742-4690-3-66","article-title":"Effects of prostratin on cyclin T1\/P-TEFb function and the gene expression profile in primary resting CD4+ T cells","volume":"3","author":"Sung","year":"2006","journal-title":"Retrovirology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1089\/hum.2005.16.1065","article-title":"Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals","volume":"16","author":"Morgan","year":"2005","journal-title":"Hum. Gene Ther."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/4\/415\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:16:35Z","timestamp":1760174195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/4\/415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":168,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["v12040415"],"URL":"https:\/\/doi.org\/10.3390\/v12040415","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]}}}